Are Analysts Bearish Valeant Pharmaceuticals International, Inc. (NYSE:VRX) After Last Week?

April 20, 2018 - By Darrin Black

Valeant Pharmaceuticals International, Inc. (NYSE:VRX) LogoInvestors sentiment decreased to 0.97 in Q4 2017. Its down 0.02, from 0.99 in 2017Q3. It dropped, as 51 investors sold Valeant Pharmaceuticals International, Inc. shares while 74 reduced holdings. 54 funds opened positions while 67 raised stakes. 169.66 million shares or 0.12% less from 169.87 million shares in 2017Q3 were reported.
Eaton Vance Mgmt reported 42,969 shares or 0% of all its holdings. Bridgewater L P holds 0.01% of its portfolio in Valeant Pharmaceuticals International, Inc. (NYSE:VRX) for 41,855 shares. Academy Capital Mgmt Tx reported 622,146 shares or 3.57% of all its holdings. Jpmorgan Chase & accumulated 0% or 1.08 million shares. Clinton Gp holds 0.18% or 100,000 shares in its portfolio. Andra Ap has invested 0.06% of its portfolio in Valeant Pharmaceuticals International, Inc. (NYSE:VRX). Pentwater Cap Mngmt L P stated it has 761,700 shares or 0.11% of all its holdings. Iron Financial Ltd Liability Corp holds 0.24% or 16,394 shares in its portfolio. Goldman Sachs Group has 3.43M shares for 0.02% of their portfolio. Continental Advsrs Ltd Company reported 154,100 shares. Tobam, France-based fund reported 736,718 shares. Stratos Wealth Ltd holds 0% or 3,061 shares in its portfolio. Systematic Financial Mgmt L P has 0.04% invested in Valeant Pharmaceuticals International, Inc. (NYSE:VRX). Thompson Davis & Company Inc owns 500 shares for 0.02% of their portfolio. Prudential Public Limited Co invested 0.02% in Valeant Pharmaceuticals International, Inc. (NYSE:VRX).

Since March 8, 2018, it had 3 insider purchases, and 0 insider sales for $876,370 activity. Shares for $241,470 were bought by Herendeen Paul on Tuesday, March 13. DE SCHUTTER RICHARD U also bought $153,400 worth of Valeant Pharmaceuticals International, Inc. (NYSE:VRX) shares.

Valeant Pharmaceuticals International, Inc. (NYSE:VRX) Ratings Coverage

Among 14 analysts covering Valeant Pharma (NYSE:VRX), 2 have Buy rating, 4 Sell and 8 Hold. Therefore 14% are positive. Valeant Pharma has $25.0 highest and $7.0 lowest target. $16.10’s average target is -7.10% below currents $17.33 stock price. Valeant Pharma had 28 analyst reports since October 30, 2017 according to SRatingsIntel. Mizuho upgraded the stock to “Hold” rating in Friday, April 6 report. CFRA downgraded Valeant Pharmaceuticals International, Inc. (NYSE:VRX) on Wednesday, February 28 to “Hold” rating. The firm has “Hold” rating given on Thursday, March 8 by Susquehanna. Canaccord Genuity maintained Valeant Pharmaceuticals International, Inc. (NYSE:VRX) rating on Monday, November 6. Canaccord Genuity has “Hold” rating and $16.0 target. Mizuho maintained the stock with “Underperform” rating in Friday, December 15 report. J.P. Morgan downgraded Valeant Pharmaceuticals International, Inc. (NYSE:VRX) on Thursday, December 14 to “Sell” rating. The firm has “Hold” rating given on Friday, November 3 by H.C. Wainwright. The stock of Valeant Pharmaceuticals International, Inc. (NYSE:VRX) has “Hold” rating given on Thursday, November 9 by H.C. Wainwright. Mizuho maintained Valeant Pharmaceuticals International, Inc. (NYSE:VRX) rating on Wednesday, November 1. Mizuho has “Sell” rating and $7.0 target. The stock of Valeant Pharmaceuticals International, Inc. (NYSE:VRX) earned “Hold” rating by BTIG Research on Monday, December 4. Below is a list of Valeant Pharmaceuticals International, Inc. (NYSE:VRX) latest ratings and price target changes.

06/04/2018 Broker: Mizuho Rating: Hold Upgrade
06/04/2018 Broker: Inc. Rating: Mizuho New Target: $11
15/03/2018 Broker: H.C. Wainwright Rating: Hold New Target: $16.0 Maintain
08/03/2018 Broker: Susquehanna Rating: Hold New Target: $17.0 Maintain
05/03/2018 Broker: Deutsche Bank Rating: Buy Upgrade
05/03/2018 Broker: Inc. Rating: Deutsche Bank New Target: $18
01/03/2018 Broker: Piper Jaffray Rating: Sell New Target: $10.0 Maintain
28/02/2018 Broker: CFRA Rating: Hold Downgrade
28/02/2018 Broker: Cantor Fitzgerald Rating: Buy New Target: $25.0 Maintain
26/02/2018 Broker: Canaccord Genuity Rating: Hold New Target: $18.0 Maintain

The stock decreased 0.40% or $0.07 during the last trading session, reaching $17.33. About 7.46M shares traded. Valeant Pharmaceuticals International, Inc. (NYSE:VRX) has risen 42.00% since April 20, 2017 and is uptrending. It has outperformed by 30.45% the S&P500.

Valeant Pharmaceuticals International, Inc. operates as a pharmaceutical and medical device firm worldwide. The company has market cap of $6.05 billion. It operates in three divisions: Bausch + Lomb/International, Branded Rx, and U.S. It has a 2.54 P/E ratio. Diversified Products.

Valeant Pharmaceuticals International, Inc. (NYSE:VRX) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: